BioSpace News Archive

A virtual autopsy is a harmless system of the autopsy. The forensic imaging strategy gives an additional edge and greater unwavering quality over conventional imaging techniques.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Cardiovascular disease is becoming more common as a result of stress, a sedentary lifestyle, and poor dietary habits.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Increase in the number of cardiac patients across the globe has created a notable rise in the need for autotransfusion of patients, thereby driving the demand for autotransfusion devices.

Photoacoustic imaging is a biochemical imaging strategy that depends on the photoacoustic impact. Non-ionizing radiations are conveyed into the tissue of the particular organism.

Matinas BioPharma announced that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion recommending MAT2203 for designation as an orphan medicinal product for the treatment of cryptococcosis.

PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing in China to treat patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors, specifically.

Centene Corporation announced that as part of its previously announced review of strategic alternatives for its international portfolio, it has signed a definitive agreement to sell to Vivalto Santé its Spanish and Central European businesses.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2022 financial results on Thursday, Aug. 4, 2022.

Analysis of nearly 23 million lab tests finds only 1 in 3 patients with latent tuberculosis were also tested for chronic hepatitis B, despite similar risk factors in patients.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2022 operating and financial results after the market close on August 2nd , 2022.